Bringing the Oncology Community Together

Genitourinary Cancer

OncLive TV - A Network of Your Peers

Dr. Burris Discusses Targeting the mTOR Pathway

Dr. Rini Discusses the VEGF Targeted Agent Axitinib

Dr. McDonald on Approved Angiogenesis Inhibitors

Dr. Rini Describes Hypertension as a Biomarker

Dr. Rini on the Progression of Advanced RCC Therapy

>>> More Genitourinary Cancer Videos

FDA Approves Axitinib for Advanced Kidney Cancer Patients

The FDA approved axitinib for the treatment of patients with advanced RCC who have failed to respond to another drug.

> Web Exclusives

Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell Carcinoma

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

Oncology & Biotech News > Conference Highlights

Tivozanib Demonstrates Better PFS Than Sorafenib, but Failed to Meet Investors Expectations

The investigational drug, tivozanib, showed improved rates of PFS in patients with advanced RCC than the already-approved sorafenib.

> Web Exclusives

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

> Web Exclusives

November 2011: Trials in Progress

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

Oncology & Biotech News > Clinical Trial Reports

Tumoral CRP Levels Correlate With Survival in Renal Cell Carcinoma

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.

Oncology Live > Specialty Focus

>>> Click here for more articles